Resmed CEO Mick Farrell addressed the latest potential threats to the CPAP therapy market during a recent webcast: The ...

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with OSA.

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...